Ultragenyx Pharmaceutical RARE Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's operating income?
- Ultragenyx Pharmaceutical (RARE) reported operating income of -$169M in Q1 2026.
- How has Ultragenyx Pharmaceutical's operating income changed year-over-year?
- Ultragenyx Pharmaceutical's operating income decreased by 18.2% year-over-year, from -$143M to -$169M.
- What is the long-term trend for Ultragenyx Pharmaceutical's operating income?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's operating income has grown at a 8.8% compound annual growth rate (CAGR), from -$381.74M to -$535.06M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.